BioCentury | Oct 4, 2019
Clinical News

Summit’s C. diff benefits for ridinilazole continue with early, sustained effect on quality of life

...Summit now has quality-of-life data for its ridinilazole to treat Clostridium difficile infections showing benefits over...
...ridinilazole vs. 7.14 for vancomycin at day 10 (p=0.0002). Of the 36 patients treated with ridinilazole...
...According to ClinicalTrials.gov, the estimated primary completion date is September 2021. Inhua Muijrers-Chen, Associate Editor Ridinilazole (smt19969, SMT 19969) Summit...
BioCentury | Jul 9, 2019
Politics & Policy

U.K. launches subscription model to pay for antibiotics

...medicines are not just reserved but used appropriately,” Roblin told BioCentury. Inhua Muijrers-Chen, Associate Editor Ridinilazole (smt19969, SMT 19969) National...
BioCentury | Dec 21, 2018
Financial News

Summit proposes $25M private placement

...following the placement. Summit plans to use the funds to support Phase III testing of ridinilazole...
...CFO in the next few days. Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT), Abingdon, U.K. Sandi Wong Ridinilazole (smt19969, SMT 19969) Summit...
BioCentury | Jun 29, 2018
Clinical News

Summit discontinues DMD program after Phase II miss

...a small molecule utrophin (UTRN) modulator. Summit will shift focus to its antibiotic programs, including ridinilazole...
...Status: Development discontinued Milestone: NA Jennie Walters ezutromid (SMT C1100, bmn 195, VOX C1100, VOXC 1100) Ridinilazole (smt19969, SMT 19969) Summit...
BioCentury | Jun 27, 2018
Clinical News

Summit craters after ending DMD program

...a small molecule utrophin UTRN modulator. Summit will shift focus to its antibiotic programs, including ridinilazole...
BioCentury | Jan 5, 2018
Company News

Summit acquires Discuva

...technology will allow it to advance candidates to treat serious bacterial infections, including lead candidate ridinilazole...
BioCentury | Nov 30, 2017
Company News

Summit, Wellcome Trust enter revenue sharing agreement for ridinilazole

...revenues generated by Summit's ridinilazole to treat Clostridium difficile infection. If a third party commercializes ridinilazole...
...by Summit from the third party licensees, excluding development or grant funding. If Summit commercializes ridinilazole...
...ridinilazole or its associated IP, in the event that Summit was not developing or commercializing ridinilazole...
BioCentury | Sep 15, 2017
Company News

BARDA awards Summit up to $62M for CDI candidate

...Advanced Research and Development Authority (BARDA) awarded the biotech up to $62 million to develop ridinilazole...
...will support two Phase III trials, which the company said will be initiated in 1H18. Ridinilazole...
...Qualified Infectious Disease Product (QIDP) designations. Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT), Abingdon, U.K. Business: Infectious Jennie Walters Ridinilazole Summit...
BioCentury | Sep 11, 2017
Company News

BARDA awards Summit up to $62M for CDI candidate

...Advanced Research and Development Authority (BARDA) awarded the biotech up to $62 million to develop ridinilazole...
...will support two Phase III trials, which the company said will be initiated in 1H18. Ridinilazole...
...gained $1.61 (11%) to $16 in New York and 30p (30%) to 242.5p in London. Jennie Walters Ridinilazole Summit...
BioCentury | Apr 18, 2016
Clinical News

Ridinilazole: Additional Phase II data

...American Phase II CoDIFy trial in 100 CDI patients showed that twice-daily 200 mg oral ridinilazole...
...14.3% vs. 34.8%). Rates of clinical cure at the end of treatment were 77.8% for ridinilazole...
...2015 & March 14, 2016). Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT), Abingdon, U.K. Product: Ridinilazole (formerly SMT19969...
Items per page:
1 - 10 of 25